cRGD-targeted gold-based nanoparticles overcome EGFR-TKI resistance of NSCLC <i>via</i> low-temperature photothermal therapy combined with sonodynamic therapy

Lv, Wenhao; Wu, Hao; Zhang, Yao; Li, Hui; Shu, Hong; Su, Chunhong; Zhu, Yangyang; Wang, Ting; Nie, Fang

doi:10.1039/d2bm01825j

Cited by 10 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,22,23,30 Nanoparticle systems are highly appealing platforms that exhibit a remarkable capacity for carrying an abundant load of drugs when compared to antibody conjugates. 32,33 The attributes of nanoparticle carriers offer an efficient resolution to the limitations encountered in traditional tumor treatment therapies, including non-specific accumulation, inadequate tumor targeting aptitude, and a diminished therapeutic impact. 34,35 It is precisely due to the rapid development of…”

Section: Discussionmentioning

confidence: 99%

Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression

Xiong,

Tong,

Xie

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression

Xiong,

Tong,

Xie

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…Breast tumor targeting and curative measures are now possible because, to the advancement of chemical synthesizing technology, which has made it possible to synthesize AuNPs with the intended characteristics in a variety of sizes and forms [45,46]. In vitro along with in vivo, the lower temperature PTT in conjunction with cRGD-GIPG sonodynamic treatment (SDT) exhibitsa strong anticancer effect versus EGFR-TKI-resistant cells of NSCLC [47].A different study put forth a number of preliminary requirements for plasmonic photothermal treatment in vitro. Pre-, during, and post-irradiation characterization, biological specimens, nanotechnologies, and PPTT experiments in vitro are the five primary areas covered by the practice [48].…”

Section: Plasmonic Photothermal Therapymentioning

confidence: 99%

Chemical potential and biomedical activity of gold nanoparticles in cancer and drug delivery systems: an updat

Soni,

Solanki

2024

Vietnam J. Sci. Technol.

View full text Add to dashboard Cite

Gold nanoparticles (AuNPs) are broadly utilized in medical fields because of its unique potential, biomedical activity and physicochemical properties. The biocompatible nature, optical properties, and minor cytotoxicity are the key features of AuNPs which make them valuable for biomedical applications. Today, AuNPs are widely used for cancer therapy, bioimaging, biosensing, radiotherapy, photodynamic therapy and drug delivery system. The present article illustrates the current progress in AuNPs synthesis, properties of AuNPs, various biomedical activity of AuNPs in therapeutic fields and drug delivery systems. Apart from numerous benefits the chemically synthesized AuNPs also creates certain level of toxicity in the living system which represents confronts of AuNPs against biomedical applications. Reducing its cytotoxic nature and development of green AuNPs can led to development of new history in field of medical science and clinical trials. Thus, the present review article deals with the compiled study of various fundamental research over AuNPs such as its chemical and bio-synthesis, biomedical and therapeutic applications viz. plasmonic photothermal therapy, photodynamic therapy, folate receptor targeting, targeted drug delivery etc. The article also finds some of its confronts against biomedical application because of its cytotoxic nature and its possible future prospects.

show abstract

“…The nanoparticle (cRGD-GIPG) ensures that the treatment is successfully delivered to the EGFR-TKI-resistant NSCLC by inhibiting the activation of the TGF-β/PDLIM5/SMAD resistance pathway and triggering drug-resistant cells to die by mitochondrial apoptosis. Thus, cRGD-GIPG exhibits strong anticancer effects against EGFR-TKI-resistant NSCLC cells both in vitro and in vivo [291]. Extensive work has also been conducted into finding novel compounds (such as allosteric modulators) [292], creating new biotechnology (such as PROTAC) [293][294][295] and suggesting effective drug combinations that successfully combat drug resistance.…”

Section: Nanotechnologymentioning

confidence: 99%

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance

Bou Antoun,

Chioni

2023

IJMS

View full text Add to dashboard Cite

One of the leading causes of death worldwide, in both men and women, is cancer. Despite the significant development in therapeutic strategies, the inevitable emergence of drug resistance limits the success and impedes the curative outcome. Intrinsic and acquired resistance are common mechanisms responsible for cancer relapse. Several factors crucially regulate tumourigenesis and resistance, including physical barriers, tumour microenvironment (TME), heterogeneity, genetic and epigenetic alterations, the immune system, tumour burden, growth kinetics and undruggable targets. Moreover, transforming growth factor-beta (TGF-β), Notch, epidermal growth factor receptor (EGFR), integrin-extracellular matrix (ECM), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), phosphoinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR), wingless-related integration site (Wnt/β-catenin), Janus kinase/signal transducers and activators of transcription (JAK/STAT) and RAS/RAF/mitogen-activated protein kinase (MAPK) signalling pathways are some of the key players that have a pivotal role in drug resistance mechanisms. To guide future cancer treatments and improve results, a deeper comprehension of drug resistance pathways is necessary. This review covers both intrinsic and acquired resistance and gives a comprehensive overview of recent research on mechanisms that enable cancer cells to bypass barriers put up by treatments, and, like “satellite navigation”, find alternative routes by which to carry on their “journey” to cancer progression.

show abstract

cRGD-targeted gold-based nanoparticles overcome EGFR-TKI resistance of NSCLC via low-temperature photothermal therapy combined with sonodynamic therapy

Abstract: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is a first-line targeted drug for the treatment of advanced non-small cell lung cancer (NSCLC) in clinical practice, but EGFR-TKI-acquired resistance limits...

Cited by 10 publications

References 59 publications

Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression

Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression

Chemical potential and biomedical activity of gold nanoparticles in cancer and drug delivery systems: an updat

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance

Contact Info

Product

Resources

About